Filtered By:
Source: International Journal of Stroke
Condition: Hemorrhagic Stroke
Management: National Institutes of Health (NIH)

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 3 results found since Jan 2013.

REVASCAT: a randomized trial of revascularization with SOLITAIRE FR® device vs. best medical therapy in the treatment of acute stroke due to anterior circulation large vessel occlusion presenting within eight‐hours of symptom onset
REVASCAT is a prospective, multicenter, randomized trial seeking to establish whether subjects meeting following main inclusion criteria: age 18‐80, baseline National Institutes of Health Stroke Scale ≥6, evidence of intracranial internal carotid artery or proximal (M1 segment) middle cerebral artery occlusion, Alberta Stroke Program Early Computed Tomography score of >7 on non‐contrast CT or >6 on diffusion‐weighted magnetic resonance imaging , ineligible for or with persistent occlusion after intravenous alteplase and procedure start within 8 hours from symptom onset, have higher rates of favorable outcome ...
Source: International Journal of Stroke - November 10, 2013 Category: Neurology Authors: Carlos A. Molina, Angel Chamorro, Àlex Rovira, Angeles Miquel, Joaquin Serena, Luis San Roman, Tudor G. Jovin, Antoni Davalos, Erik Cobo Tags: Protocols Source Type: research

Thrombectomy in patients ineligible for iv tPA (THRILL)
DiscussionWhether mechanical thrombectomy in patients with acute ischemic stroke who are not eligible for intravenous thrombolysis with recombinant tissue plasminogen activator improves clinical outcomes is unclear. ‘Thrombectomy in patients ineligible for iv tPA’ may change clinical practice by providing evidence of an effective and safe treatment for such patients.
Source: International Journal of Stroke - June 4, 2015 Category: Neurology Authors: Martin Bendszus, Götz Thomalla, Michael Knauth, Werner Hacke, Susanne Bonekamp, Jens Fiehler Tags: Protocol Source Type: research

A multicenter, randomized, controlled study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits with Intra‐Arterial therapy (EXTEND‐IA)
Background and HypothesisThrombolysis with tissue plasminogen activator is proven to reduce disability when given within 4·5 h of ischemic stroke onset. However, tissue plasminogen activator only succeeds in recanalizing large vessel arterial occlusion in a minority of patients. We hypothesized that anterior circulation ischemic stroke patients, selected with ‘dual target’ vessel occlusion and evidence of salvageable brain using computed tomography or magnetic resonance imaging ‘mismatch’ within 4·5 h of onset, would have improved reperfusion and early neurological improvement when treated with intra‐arteri...
Source: International Journal of Stroke - November 10, 2013 Category: Neurology Authors: Bruce C. V. Campbell, Peter J. Mitchell, Bernard Yan, Mark W. Parsons, Søren Christensen, Leonid Churilov, Richard J. Dowling, Helen Dewey, Mark Brooks, Ferdinand Miteff, Christopher Levi, Martin Krause, Timothy J. Harrington, Kenneth C. Faulder, Brendan Tags: Protocols Source Type: research